CClinicalTrials.gg
CompletedNCT04949230Updated Feb 29, 2024

A Retrospective Study of COVID-19 Treatments

An observational study in Covid19, COVID-19 Pneumonia and COVID-19 Respiratory Infection, sponsored by ProgenaBiome. Completed at 1 site in United States. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by ProgenaBiome · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
300
Ages
18 Months and older
Sex
All
01

Study summary

Surveys administered to subjects who have recovered from COVID-19 to assess how effective their treatment was.

Read the detailed description

Subjects who have recovered from COVID-19 will answer questions regarding the severity of their illness, symptoms experienced, what treatment they received, and how long they were ill.

02

Conditions studied

  • Covid19
  • COVID-19 Pneumonia
  • COVID-19 Respiratory Infection
  • COVID-19 Acute Bronchitis
  • COVID-19 Acute Respiratory Distress Syndrome
  • COVID-19 Lower Respiratory Infection
  • SARS-CoV2 Infection
  • SARS-CoV-2 Acute Respiratory Disease
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 300 is above the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ProgenaBiome is the lead sponsor of 47 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

  1. Refusal to sign informed consent form

Inclusion criteria

  1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
  2. Male or female of 18 years of age or older
  3. Diagnosis of COVID-19 infection by RT- PCR
  4. Recovery from COVID-19

Exclusion criteria

Exclusion Criteria:

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
300 participants (actual)
Patient registry
No

Groups and cohorts

  • COVID-19 Patients

    Subjects who have recovered from COVID-19

    Other: No Intervention Used

Interventions

  • OtherNo Intervention Used

    There is no intervention in this study

06

What researchers measure

Primary outcomes

  1. Survey Response

    Answers given by subjects on their recovery from COVID-19

    Time frame: One hour

07

Study locations

1 site
  • Ginger Aurella
    Ventura, California 93003, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04949230
Lead sponsor
ProgenaBiome
Responsible party
Sponsor
First posted
Jul 2, 2021
Start date
Feb 19, 2021
Primary completion
Feb 15, 2024
Completion
Feb 15, 2024
Last update
Feb 29, 2024

Study contacts

Sabine Hazan, MD
study director · ProgenaBiome

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion